Evaluation of the efficacy of a bivalent inactivated whole-cell vaccine against Edwardsiella tarda and Vibrio anguillarum in Tilapia (Oreochromis niloticus)

Bacterial co-infections constrain tilapia aquaculture. We evaluated the efficacy of an adjuvant-free, formalin-inactivated bivalent whole-cell vaccine combining Edwardsiella tarda and Vibrio anguillarum in Nile tilapia. Fish received the bivalent formulation, matched monovalent vaccines, or phosphate-buffered saline. Systemic and skin-mucus immunoglobulin M levels were quantified by indirect enzyme-linked immunosorbent assay, and serum and mucus bactericidal activity were assessed at 1, 7, 14, and 21-days post-vaccination. At 21 days post-vaccination, fish were challenged intraperitoneally with E. tarda or V. anguillarum, or both. By 14–21 days post-vaccination, the bivalent vaccine induced strong systemic and mucosal immunoglobulin M responses and increased bactericidal activity; across readouts, responses were significantly greater than (p < 0.05) or equal to (p > 0.05) the corresponding monovalent vaccine. After challenge with E. tarda, 21-day post-challenge survival was higher in the bivalent (54.17%, Relative Percent Survival = 38.9%) than in the monovalent (29.17%) or control (25.00%) group (both p < 0.05). After V. anguillarum challenge, survival was similar in the bivalent (87.50%, Relative Percent Survival = 78.6%) and monovalent (75.00%) groups (p > 0.05), both of which showed greater survival than the control (41.67%) (p < 0.05). After mixed E. tarda + V. anguillarum challenge, survival was significantly higher (50.00%, Relative Percent Survival = 47.8%) in the bivalent group than in the control group (4.17%) (p < 0.05). No acute adverse reactions or behavioral abnormalities were observed. These findings indicate that an adjuvant-free bivalent vaccine elicits robust mid- to late-phase humoral responses and provides broad protection without evidence of antigenic interference, supporting a practical polyvalent strategy where E. tarda and V. anguillarum co-circulate.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-11-21
DOI
https://doi.org/10.5281/zenodo.18001946
Primary Topic
Aquaculture disease management and microbiota
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of the efficacy of a bivalent inactivated whole-cell vaccine against Edwardsiella tarda and Vibrio anguillarum in Tilapia (Oreochromis niloticus)

Kunihiko Futami, Masato Endo, Zheyu LIU
Zenodo (CERN European Organization for Nuclear Research)
Aquaculture disease management and microbiota
article

Evaluation of the efficacy of a bivalent inactivated whole-cell vaccine against Edwardsiella tarda and Vibrio anguillarum in Tilapia (Oreochromis niloticus)

Kunihiko Futami, Masato Endo, Zheyu LIU
article en

Abstract

Bacterial co-infections constrain tilapia aquaculture. We evaluated the efficacy of an adjuvant-free, formalin-inactivated bivalent whole-cell vaccine combining Edwardsiella tarda and Vibrio anguillarum in Nile tilapia. Fish received the bivalent formulation, matched monovalent vaccines, or phosphate-buffered saline. Systemic and skin-mucus immunoglobulin M levels were quantified by indirect enzyme-linked immunosorbent assay, and serum and mucus bactericidal activity were assessed at 1, 7, 14, and 21-days post-vaccination. At 21 days post-vaccination, fish were challenged intraperitoneally with E. tarda or V. anguillarum, or both. By 14–21 days post-vaccination, the bivalent vaccine induced strong systemic and mucosal immunoglobulin M responses and increased bactericidal activity; across readouts, responses were significantly greater than (p < 0.05) or equal to (p > 0.05) the corresponding monovalent vaccine. After challenge with E. tarda, 21-day post-challenge survival was higher in the bivalent (54.17%, Relative Percent Survival = 38.9%) than in the monovalent (29.17%) or control (25.00%) group (both p < 0.05). After V. anguillarum challenge, survival was similar in the bivalent (87.50%, Relative Percent Survival = 78.6%) and monovalent (75.00%) groups (p > 0.05), both of which showed greater survival than the control (41.67%) (p < 0.05). After mixed E. tarda + V. anguillarum challenge, survival was significantly higher (50.00%, Relative Percent Survival = 47.8%) in the bivalent group than in the control group (4.17%) (p < 0.05). No acute adverse reactions or behavioral abnormalities were observed. These findings indicate that an adjuvant-free bivalent vaccine elicits robust mid- to late-phase humoral responses and provides broad protection without evidence of antigenic interference, supporting a practical polyvalent strategy where E. tarda and V. anguillarum co-circulate.

Zenodo (CERN European Organization for Nuclear Research)
Tokyo University of Marine Science and Technology (JP)
Life below water
Openalex Percentile: Top 37%
Aquaculture disease management and microbiota
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.